Lynparza Approved in the US for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

Article Link: Lynparza Approved in the US for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

20 May 2020 — AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for patients with homologous recombination repair (HRR)…

Source: FDA New Drug Approvals